Successful treatment of rapid progressive interstitial lung disease in a case of anti-Zo antibody positive anti-synthetase syndrome

作者全名："Li, Yongxia; Liu, Gang; Yu, Fengjiao; Jiang, Yu"

作者地址："[Li, Yongxia; Yu, Fengjiao; Jiang, Yu] Chongqing Med Univ, Univ Town Hosp, Dept Resp & Crit Care Med, Chongqing 401331, Peoples R China; [Liu, Gang] Chongqing Med Univ, Univ Town Hosp, Dept Crit Care Med, Chongqing, Peoples R China"

通信作者："Jiang, Y (通讯作者)，Chongqing Med Univ, Univ Town Hosp, Dept Resp & Crit Care Med, Chongqing 401331, Peoples R China."

来源：INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000870790300001

JCR分区：Q3

影响因子：2.5

年份：2022

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：antisynthetase syndrome; anti-Zo; case report; interstitial lung disease; tacrolimus

摘要："Background Anti-synthetase syndrome (ASS) is a chronic multisystemic autoimmune disease characterized by detectable anti-aminoacyl-transfer-RNA antibodies. Interstitial lung disease (ILD) in anti-synthetase syndrome patients is often severe and rapidly progressive. Anti-Zo (phenylalanyl) antibody is reported rarely in ASS. Therefore, the appropriate treatment of anti-Zo positive ASS is unclear. Case presentation Here we present a case of anti-Zo-positive ASS with rapid progressive ILD (RP-ILD) in a Chinese patient successfully treated with a combination of systemic corticosteroids and tacrolimus. Conclusion We reviewed 13 anti-Zo-positive ASS patients (including our case) and summarized clinical features that have some differences with other ASS. Anti-Zo-positive ASS is a rare autoimmune disease with a high burden of ILD, is often severe and rapidly progressive. Corticosteroids with tacrolimus may improve patient outcomes in anti-Zo antibody positive ASS with RP-ILD."

基金机构：Chongqing Natural Science Foundation Committee [cstc2020jcyj-msxmX0359]

基金资助正文："Project of Chongqing Natural Science Foundation Committee, Grant/Award Number: cstc2020jcyj-msxmX0359"